BC Week In Review | Sep 20, 2019
Company News

China exempts 12 cancer drugs from tariffs

China is exempting 12 cancer drugs from tariffs imposed on U.S. goods, the first time China has offered tariff relief since the trade war began last year. The 12 drugs include Iressa gefitinib and Tomudex...
BC Extra | Mar 13, 2019
Politics & Policy

China releases timeline, priority diseases for revised reimbursement list

China's National Medical Insurance Administration released its plan for issuing a revised National Drug Reimbursement List Wednesday, describing which types of drugs will have priority for inclusion and sketching out a timeline for a revision...
BC Innovations | Apr 7, 2016
Distillery Therapeutics

Therapeutics: Thymidylate synthetase (TYMS)

Cancer INDICATION: Liver cancer In vitro and mouse studies identified an oral phosphoramidate-based prodrug of the TYMS inhibitor floxuridine that could help treat hepatocellular carcinoma (HCC). Chemical synthesis of benzylamine phosphoramidate analogs of floxuridine followed...
BC Innovations | Mar 3, 2016
Targets & Mechanisms

Targeting TMP

In a study in Science , chemists at the University of Iowa reported that they have worked out the major steps in a bacteria-specific pathway for synthesizing the nucleotide TMP, opening new possibilities for antibiotics that...
BC Week In Review | Oct 18, 2010
Company News

Hospira, AstraZeneca sales and marketing update

Hospira launched Tomudex raltitrexed in Portugal, Czech Republic and Hungary for malignant pleural mesothelioma. In 2007, Hospira acquired marketing rights to the injected cytotoxic thymidylate synthase inhibitor from AstraZeneca, which markets the product in the...
BC Week In Review | Jan 5, 2009
Clinical News

AstraZeneca, Debiopharm, Hospira, Pfizer, sanofi-aventis regulatory update

AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K.   Debiopharm S.A. , Lausanne, Switzerland   Hospira Inc. (NYSE:HSP), Lake Forest, Ill.   Pfizer Inc. (NYSE:PFE), New York, N.Y.   sanofi-aventis Group (Euronext:SAN; NYSE:SNY), Paris, France   Business: Cancer...
BC Week In Review | Mar 11, 2002
Clinical News

Colorectal cancer therapeutics regulatory update

The U.K.'s National Institute for Clinical Excellence (NICE) issued guidance on the use of three advanced colorectal cancer treatments recommending only selective uses for all of them. The Institute recommended that Eloxatin oxaliplatin from Sanofi-Synthelabo...
BC Extra | Mar 8, 2002
Politics & Policy

NICE cancer product guidance

The National Institute for Clinical Excellence (NICE) issued its guidance on the use of 3 advanced colorectal cancer treatments recommending only selective uses for all of them. The institute recommended that Eloxatin oxaliplatin from Sanofi...
BioCentury | May 21, 2001
Tools & Techniques

EGFr: Being 1st may not matter

Epidermal growth factor receptor antagonists appear poised to be the next class of targeted therapies for cancer, attracting both investor and public visibility for companies nearing the milestone of an NDA filing. But even though...
Items per page:
1 - 9 of 9